Califf gives rationale for deferring Sarepta decision

FDA Commissioner Robert Califf chose not to make the approval decision for Exondys 51 eteplirsen from Sarepta Therapeutics Inc. (NASDAQ:SRPT)

Read the full 202 word article

User Sign In